18:10 , Aug 31, 2018 |  BC Week In Review  |  Clinical News

TB Alliance starts pivotal trial of four-drug regimen

The Global Alliance for TB Drug Development (TB Alliance) began the pivotal Phase IIc SimpliciTB trial evaluating an oral four-drug regimen called BPaMZ to treat tuberculosis. SimpliciTB will compare BPaMZ, which comprises a once-daily combination of...
20:43 , Aug 28, 2018 |  BC Extra  |  Clinical News

TB Alliance starts pivotal trial of four-drug regimen

The Global Alliance for TB Drug Development (TB Alliance) began the pivotal Phase IIc SimpliciTB trial evaluating an oral four-drug regimen called BPaMZ to treat tuberculosis. SimpliciTB will compare BPaMZ, which comprises a once-daily combination of...
23:48 , Aug 8, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Pneumonia; bacterial infection Cell culture and mouse studies identified a methoxyquinolone-based compound that could help treat bacterial pneumonia. Structure-based design, chemical synthesis and testing in bacterial cultures of methoxyquinolone analogs yielded a compound that inhibited...
15:30 , May 25, 2018 |  BC Week In Review  |  Clinical News

Nabriva's lefamulin meets in Phase III LEAP 2 trial for CABP

Nabriva Therapeutics plc (NASDAQ:NBRV) reported a higher incidence of GI adverse events in patients who received oral lefamulin (BC-3781) in the Phase III LEAP 2 trial to treat moderate community-acquired bacterial pneumonia (CABP). While the...
22:45 , May 21, 2018 |  BC Extra  |  Clinical News

Nabriva falls on GI safety in second Phase III for CABP

Nabriva Therapeutics plc (NASDAQ:NBRV) lost $0.90 (17%) to $4.53 on Monday after reporting a higher incidence of GI adverse events in patients who received oral lefamulin (BC-3781) in the Phase III LEAP 2 trial to...
20:36 , Feb 2, 2018 |  BC Week In Review  |  Clinical News

Da Volterra's DAV132 meets in Phase I for antibiotic-induced dysbiosis

Da Volterra (Paris, France) reported data from the open-label, French Phase I DAV132-CL-1002 trial in 44 healthy volunteers showing that DAV132 met the primary endpoint by effectively capturing residual moxifloxacin in the colon. Specifically, co-administration...
20:11 , Sep 22, 2017 |  BC Week In Review  |  Clinical News

Nabriva's lefamulin meets in Phase III LEAP 1 trial for CABP

Nabriva Therapeutics plc (NASDAQ:NBRV) reported that IV-to-oral lefamulin (BC-3781) met the FDA- and EMA-defined primary endpoints in the double-blind, international Phase III LEAP 1 trial to treat moderate to severe community-acquired bacterial pneumonia (CABP). Top-line...
20:24 , Sep 18, 2017 |  BC Extra  |  Clinical News

Nabriva rises on Phase III CABP success

Nabriva Therapeutics plc (NASDAQ:NBRV) jumped $2.01 (29%) to $8.87 on Monday after reporting that IV-to-oral lefamulin (BC-3781) met the FDA- and EMA-defined primary endpoints in the Phase III LEAP 1 trial to treat moderate to...
23:13 , Apr 13, 2017 |  BC Week In Review  |  Clinical News

Lefamulin: Completed Ph III enrollment

Nabriva completed enrollment of 550 patients in the double-blind, international Phase III LEAP 1 trial comparing IV and oral lefamulin vs. IV and oral moxifloxacin with or without Zyvox linezolid for 7 or 10 days....
19:18 , Apr 7, 2017 |  BC Week In Review  |  Clinical News

Omadacycline: Ph III OPTIC data

Top-line data from 774 patients with CABP in the ITT population of the double-blind, international Phase III OPTIC trial showed that once-daily IV-to-oral omadacycline for 7-14 days met the FDA-defined primary endpoint of non-inferiority to...